Ryan W Gan1, M Kristen Demoruelle2, Kevin D Deane2, Michael H Weisman3, Jane H Buckner4, Peter K Gregersen5, Ted R Mikuls6, James R O'Dell6, Richard M Keating7, Tasha E Fingerlin8, Gary O Zerbe9, Michael J Clare-Salzler10, V Michael Holers2, Jill M Norris1. 1. Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado, USA. 2. Division of Rheumatology, University of Colorado, Aurora, Colorado, USA. 3. Cedars-Sinai Medical Center, Los Angeles, California, USA. 4. Benaroya Research Institute at Virginia Mason, Seattle, Washington, USA. 5. Feinstein Institute for Medical Research and North Shore-Long Island Jewish Health System, Manhasset, New York, USA. 6. Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, Nebraska, USA. 7. Scripps Health, La Jolla, California, USA. 8. National Jewish Health, Denver, Colorado, USA. 9. Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, Colorado, USA. 10. Department of Pathology, Immunology and Laboratory Medicine, University of Florida, Gainesville, Florida, USA.
Abstract
OBJECTIVES: Previously, we found that omega-3 fatty acids (n-3 FAs) were inversely associated with anti-cyclic citrullinated peptide (anti-CCP) positivity in participants at risk for future rheumatoid arthritis (RA). We investigated whether n-3 FAs were also associated with rheumatoid factor (RF) positivity and whether these associations were modified by shared epitope (SE) positivity. METHODS: The Studies of the Etiology of RA (SERA) cohort includes RA-free participants who are at increased risk for RA. We conducted a nested case-control study (n=136) to determine the association between RF and anti-CCP2 positivity and n-3 FA percentage in erythrocyte membranes (n-3 FA% in red blood cells (RBCs)). Additionally, in the baseline visit of the SERA cohort (n=2166), we evaluated the association between reported n-3 FA supplement use and prevalence of RF and anti-CCP2. We assessed SE positivity as an effect modifier. RESULTS: In the case-control study, increasing n-3 FA% in RBCs was inversely associated with RF positivity in SE-positive participants (OR 0.27, 95% CI 0.10 to 0.79), but not SE-negative participants. Similar associations were seen with anti-CCP positivity in SE-positive participants (OR 0.42, 95% CI 0.20 to 0.89), but not SE-negative participants. In the SERA cohort at baseline, n-3 FA supplement use was associated with a lower prevalence of RF positivity in SE-positive participants (OR 0.32, 95% CI 0.12 to 0.82), but not SE-negative participants; similar but non-significant trends were observed with anti-CCP2. CONCLUSIONS: The potential protective effect of n-3 FAs on RA-related autoimmunity may be most pronounced in those who exhibit HLA class II genetic susceptibility to RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
OBJECTIVES: Previously, we found that omega-3 fatty acids (n-3 FAs) were inversely associated with anti-cyclic citrullinated peptide (anti-CCP) positivity in participants at risk for future rheumatoid arthritis (RA). We investigated whether n-3 FAs were also associated with rheumatoid factor (RF) positivity and whether these associations were modified by shared epitope (SE) positivity. METHODS: The Studies of the Etiology of RA (SERA) cohort includes RA-free participants who are at increased risk for RA. We conducted a nested case-control study (n=136) to determine the association between RF and anti-CCP2 positivity and n-3 FA percentage in erythrocyte membranes (n-3 FA% in red blood cells (RBCs)). Additionally, in the baseline visit of the SERA cohort (n=2166), we evaluated the association between reported n-3 FA supplement use and prevalence of RF and anti-CCP2. We assessed SE positivity as an effect modifier. RESULTS: In the case-control study, increasing n-3 FA% in RBCs was inversely associated with RF positivity in SE-positive participants (OR 0.27, 95% CI 0.10 to 0.79), but not SE-negative participants. Similar associations were seen with anti-CCP positivity in SE-positive participants (OR 0.42, 95% CI 0.20 to 0.89), but not SE-negative participants. In the SERA cohort at baseline, n-3 FA supplement use was associated with a lower prevalence of RF positivity in SE-positive participants (OR 0.32, 95% CI 0.12 to 0.82), but not SE-negative participants; similar but non-significant trends were observed with anti-CCP2. CONCLUSIONS: The potential protective effect of n-3 FAs on RA-related autoimmunity may be most pronounced in those who exhibit HLA class II genetic susceptibility to RA. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Ryan W Gan; Leendert A Trouw; Jing Shi; René E M Toes; Tom W J Huizinga; M Kristen Demoruelle; Jason R Kolfenbach; Gary O Zerbe; Kevin D Deane; Jess D Edison; William R Gilliland; Jill M Norris; V Michael Holers Journal: J Rheumatol Date: 2015-01-15 Impact factor: 4.666
Authors: Jason R Kolfenbach; Kevin D Deane; Lezlie A Derber; Colin O'Donnell; Michael H Weisman; Jane H Buckner; Vivian H Gersuk; Shan Wei; Ted R Mikuls; James O'Dell; Peter K Gregersen; Richard M Keating; Jill M Norris; V Michael Holers Journal: Arthritis Rheum Date: 2009-12-15
Authors: Bo Ding; Leonid Padyukov; Emeli Lundström; Mark Seielstad; Robert M Plenge; Jorge R Oksenberg; Peter K Gregersen; Lars Alfredsson; Lars Klareskog Journal: Arthritis Rheum Date: 2009-01
Authors: Cesar Ramos-Remus; Jose Dionisio Castillo-Ortiz; Luis Aguilar-Lozano; Jorge Padilla-Ibarra; Carlos Sandoval-Castro; Cesar Omar Vargas-Serafin; Hector de la Mora-Molina; Ariadna Ramos-Gomez; Adriana Sanchez-Ortiz; Hilario Avila-Armengol; Francisco Javier Aceves-Avila Journal: Arthritis Rheumatol Date: 2015-11 Impact factor: 10.995
Authors: Maria G Prado; Maura D Iversen; Zhi Yu; Rachel Miller Kroouze; Nellie A Triedman; Sarah S Kalia; Bing Lu; Robert C Green; Elizabeth W Karlson; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2018-10 Impact factor: 4.794
Authors: Julia A Ford; Xinyi Liu; Allison A Marshall; Alessandra Zaccardelli; Maria G Prado; Charlene Wiyarand; Bing Lu; Elizabeth W Karlson; Peter H Schur; Kevin D Deane; Jeffrey A Sparks Journal: Arthritis Care Res (Hoboken) Date: 2019-12 Impact factor: 4.794
Authors: Kevin D Deane; M Kristen Demoruelle; Lindsay B Kelmenson; Kristine A Kuhn; Jill M Norris; V Michael Holers Journal: Best Pract Res Clin Rheumatol Date: 2017-09-18 Impact factor: 4.098
Authors: Jeffrey A Sparks; Maura D Iversen; Zhi Yu; Nellie A Triedman; Maria G Prado; Rachel Miller Kroouze; Sarah S Kalia; Michael L Atkinson; Elinor A Mody; Simon M Helfgott; Derrick J Todd; Paul F Dellaripa; Bonnie L Bermas; Karen H Costenbader; Kevin D Deane; Bing Lu; Robert C Green; Elizabeth W Karlson Journal: Arthritis Care Res (Hoboken) Date: 2018-04-16 Impact factor: 4.794
Authors: Ryan W Gan; Elizabeth A Bemis; M Kristen Demoruelle; Christopher C Striebich; Stacey Brake; Marie L Feser; LauraKay Moss; Michael Clare-Salzler; V Michael Holers; Kevin D Deane; Jill M Norris Journal: Rheumatology (Oxford) Date: 2017-12-01 Impact factor: 7.580